Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q1 2022
Net profit, assets, equity and cash flow for Q1 2022, against the same period a year earlier, from the published financial statements.
Net profit30.67 millionEGP
Total assets641 millionEGP
Shareholders' equity334 millionEGP
Operating cash flow34.73 millionEGP
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q1 2022 was about 30.67 million EGP.
- Total assets at the end of Q1 2022 were about 641 million EGP, and shareholders' equity about 334 million EGP.
- Operating cash flow for Q1 2022 was positive at 34.73 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit30.67 million——
Gross profit107 million——
Total assets641 million——
Total liabilities307 million——
Shareholders' equity334 million——
Total liabilities and equity641 million——
Operating cash flow34.73 million——
Investing cash flow-42.97 thousand——
Financing cash flow19.03 million——
Net change in cash53.71 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy